Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene

H. Lhotska, Z. Zemanova, H. Cechova, S. Ransdorfova, L. Lizcova, F. Kramar, Z. Krejcik, K. Svobodova, D. Bystricka, P. Hrabal, A. Dohnalova, K. Michalova,

. 2015 ; 54 (11) : 655-667. [pub] 20150825

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16020362

Grant support
NT13212 MZ0 CEP Register

Diffuse astrocytomas and oligodendrogliomas (WHO grade II) are the most common histological subtypes of low-grade gliomas (LGGs). Several molecular and epigenetic markers have been identified that predict tumor progression. Our aim was in detail to investigate the genetic and epigenetic background of LGGs and to identify new markers that might play a role in tumor behavior. Twenty-three patients with oligodendroglioma or oligoastrocytoma (LGO) and 22 patients with diffuse astrocytoma (LGA) were investigated using several molecular-cytogenetic and molecular methods to assess their copy number variations, mutational status and level of promoter methylation. The most frequent findings were a 1p/19q codeletion in 83% of LGO and copy-neutral loss of heterozygosity (CN-LOH) of 17p in 72% of LGA. Somatic mutations in the isocitrate dehydrogenase 1 or 2 (IDH1/IDH2) genes were detected in 96% of LGO and 91% of LGA. The O-6-methylguanine-DNA-methyltransferase (MGMT) promoter was methylated in 83% of LGO and 59% of LGA. MutL homolog 3 (MLH3) promoter methylation was observed in 61% of LGO and 27% of LGA. Methylation of the MGMT promoter, 1p/19q codeletion, mutated IDH1, and CN-LOH of 17p were the most frequent genetic aberrations in LGGs. The findings were more diverse in LGA than in LGO. To the best of our knowledge, this is the first time description of methylation of the MLH3 gene promoter in LGGs. Further studies are required to determine the role of the methylated MLH3 promoter and the other aberrations detected.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020362
003      
CZ-PrNML
005      
20181009105709.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/gcc.22266 $2 doi
024    7_
$a 10.1002/gcc.22266 $2 doi
035    __
$a (PubMed)26303387
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lhotská, Halka $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $7 xx0276414
245    10
$a Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene / $c H. Lhotska, Z. Zemanova, H. Cechova, S. Ransdorfova, L. Lizcova, F. Kramar, Z. Krejcik, K. Svobodova, D. Bystricka, P. Hrabal, A. Dohnalova, K. Michalova,
520    9_
$a Diffuse astrocytomas and oligodendrogliomas (WHO grade II) are the most common histological subtypes of low-grade gliomas (LGGs). Several molecular and epigenetic markers have been identified that predict tumor progression. Our aim was in detail to investigate the genetic and epigenetic background of LGGs and to identify new markers that might play a role in tumor behavior. Twenty-three patients with oligodendroglioma or oligoastrocytoma (LGO) and 22 patients with diffuse astrocytoma (LGA) were investigated using several molecular-cytogenetic and molecular methods to assess their copy number variations, mutational status and level of promoter methylation. The most frequent findings were a 1p/19q codeletion in 83% of LGO and copy-neutral loss of heterozygosity (CN-LOH) of 17p in 72% of LGA. Somatic mutations in the isocitrate dehydrogenase 1 or 2 (IDH1/IDH2) genes were detected in 96% of LGO and 91% of LGA. The O-6-methylguanine-DNA-methyltransferase (MGMT) promoter was methylated in 83% of LGO and 59% of LGA. MutL homolog 3 (MLH3) promoter methylation was observed in 61% of LGO and 27% of LGA. Methylation of the MGMT promoter, 1p/19q codeletion, mutated IDH1, and CN-LOH of 17p were the most frequent genetic aberrations in LGGs. The findings were more diverse in LGA than in LGO. To the best of our knowledge, this is the first time description of methylation of the MLH3 gene promoter in LGGs. Further studies are required to determine the role of the methylated MLH3 promoter and the other aberrations detected.
650    _2
$a astrocytom $x genetika $x metabolismus $7 D001254
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a nádory mozku $x genetika $x metabolismus $7 D001932
650    _2
$a transportní proteiny $x genetika $x metabolismus $7 D002352
650    _2
$a kohortové studie $7 D015331
650    12
$a metylace DNA $7 D019175
650    12
$a epigeneze genetická $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a oligodendrogliom $x genetika $x metabolismus $7 D009837
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zemanová, Zuzana, $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $d 1962- $7 nlk20050170627
700    1_
$a Čechová, Hana $u Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic. $7 xx0146598
700    1_
$a Ransdorfová, Šárka $u Cytogenetic Department, Institute of Hematology and Blood transfusion, Prague 2, Czech Republic. $7 xx0128449
700    1_
$a Lizcová, Libuše $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $7 xx0128719
700    1_
$a Kramář, Filip $u Department of Neurosurgery, Central Military Hospital and 1st Faculty of Medicine, Charles University, Prague 6, Czech Republic. $7 xx0061774
700    1_
$a Krejčík, Zdeněk $u Department of Molecular Genetics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic. $7 xx0125786
700    1_
$a Svobodová, Karla $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $7 xx0276416
700    1_
$a Bystřická, Dagmar $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $7 xx0037581
700    1_
$a Hrabal, Petr. $u Department of Neurosurgery, Central Military Hospital and 1st Faculty of Medicine, Charles University, Prague 6, Czech Republic. $7 xx0127434
700    1_
$a Dohnalová, Alena $u Institute of Physiology, 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. $7 xx0062948
700    1_
$a Michalová, Kyra, $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic. Cytogenetic Department, Institute of Hematology and Blood transfusion, Prague 2, Czech Republic. $d 1942- $7 nlk19990073558
773    0_
$w MED00001898 $t Genes, chromosomes & cancer $x 1098-2264 $g Roč. 54, č. 11 (2015), s. 655-667
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26303387 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20181009110157 $b ABA008
999    __
$a ok $b bmc $g 1155032 $s 944890
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 54 $c 11 $d 655-667 $e 20150825 $i 1098-2264 $m Genes, chromosomes & cancer $n Genes Chromosom Cancer $x MED00001898
GRA    __
$a NT13212 $p MZ0
LZP    __
$a Pubmed-20160722
Back

Find record

Citation metrics

Archiving options